Analysis of patients with GAD antibodies and cerebellar ataxia
Retrospective Analysis of the French National Cohort of Patients With GAD Antibodies and Cerebellar Ataxia
Hospices Civils de Lyon · NCT06334900
This study looks at patients with GAD antibodies and cerebellar ataxia to see how these antibodies might be causing symptoms like confusion and muscle stiffness.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon (other) |
| Locations | 1 site (Bron) |
| Trial ID | NCT06334900 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes data from the French National Cohort of patients who have GAD-receptor antibodies associated with cerebellar ataxia. It focuses on understanding the neurological conditions linked to high levels of GAD65 antibodies, which can lead to symptoms such as confusion, memory loss, and muscle stiffness. The study aims to identify the autoimmune causes of these symptoms by examining serum and cerebrospinal fluid samples for specific antibody markers. By retrospectively analyzing patient data, the study seeks to enhance the understanding of GAD antibody-related neurological disorders.
Who should consider this trial
Good fit: Ideal candidates for this study are patients exhibiting neurological symptoms associated with GAD antibodies and diagnosed with cerebellar ataxia.
Not a fit: Patients who have tested positive for other antibodies or lack sufficient data may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve diagnosis and treatment strategies for patients with GAD antibody-related neurological conditions.
How similar studies have performed: Other studies have shown success in understanding autoimmune neurological conditions related to GAD antibodies, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * neurological symptoms with GAD antibody * GAD antibody in sera and/or CSF * patient with cerebellar ataxia Exclusion Criteria: * tested positive to another antibody. * no data * any test in paraneoplastic neurological syndrome and autoimmune encephalitis center
Where this trial is running
Bron
- Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est — Bron, France (RECRUITING)
Study contacts
- Study coordinator: Jérôme Honnorat, professor
- Email: jerome.honnorat@chu-lyon.fr
- Phone: +33 4 72 35 78 06
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: GAD-receptor Antibodies-associated Encephalitis